Core Insights - BioCardia, Inc. has been granted Japanese Patent No. 7641330 for its "Radial and Transendocardial Delivery Catheter," which will expire on or after September 30, 2034, enhancing its patent position in minimally invasive catheter-based delivery systems for cell and gene therapies [1][2] Company Overview - BioCardia is a global leader in cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary diseases, with its headquarters in Sunnyvale, California [4] - The company has developed two main biotherapeutic platforms: CardiAMP (autologous) and CardiALLO (allogeneic) cell therapies, with three clinical stage product candidates currently in development [4] Patent and Technology - The newly issued patent describes minimally invasive interventional biotherapeutic delivery catheters designed to deliver biologic therapies directly to the heart, minimizing off-target toxicities and avoiding surgical access [2][3] - BioCardia's Helix System is noted as the only catheter-based intramyocardial delivery system currently in active clinical use, supported by data indicating it is the safest and most efficient method for biotherapeutic delivery to the heart [2][3] Market Position - Japan is identified as a crucial initial market for BioCardia's therapies due to its commitment to supporting novel and cost-effective cell therapy solutions for its aging population, alongside the development of the Japanese stem cell industry [2]
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System